- Home
- CURV vs NBP Comparison
CURV vs NBP Comparison
Compare CURV & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURV | NBP |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.2M | 173.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CURV | NBP |
|---|---|---|
| Price | $1.89 | $1.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $1.59 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 574.6K | 521.3K |
| Earning Date | 06-04-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,000,092,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $1.46 |
| 52 Week High | $3.14 | $5.19 |
Technical Indicators
Market Signals| Indicator | CURV | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 41.58 |
| Support Level | $1.03 | N/A |
| Resistance Level | $1.93 | $1.95 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 74.51 | 38.18 |
Price Performance
Historical ComparisonAbout CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand in North America dedicated to offering a diverse assortment of stylish apparel, intimates, and accessories skillfully designed for curvy women. Its extensive collection features high-quality merchandise, including tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of its e-Commerce platform and stores.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.